- Home
- EBS vs ZVRA Comparison
EBS vs ZVRA Comparison
Compare EBS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- ZVRA
- Stock Information
- Founded
- EBS 1998
- ZVRA 2006
- Country
- EBS United States
- ZVRA United States
- Employees
- EBS N/A
- ZVRA N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- ZVRA Health Care
- Exchange
- EBS Nasdaq
- ZVRA Nasdaq
- Market Cap
- EBS 518.0M
- ZVRA 458.5M
- IPO Year
- EBS 2006
- ZVRA 2015
- Fundamental
- Price
- EBS $10.20
- ZVRA $8.15
- Analyst Decision
- EBS Strong Buy
- ZVRA Strong Buy
- Analyst Count
- EBS 3
- ZVRA 7
- Target Price
- EBS $14.33
- ZVRA $21.20
- AVG Volume (30 Days)
- EBS 1.1M
- ZVRA 492.6K
- Earning Date
- EBS 03-04-2025
- ZVRA 11-12-2024
- Dividend Yield
- EBS N/A
- ZVRA N/A
- EPS Growth
- EBS N/A
- ZVRA N/A
- EPS
- EBS N/A
- ZVRA N/A
- Revenue
- EBS $1,125,500,000.00
- ZVRA $24,489,000.00
- Revenue This Year
- EBS $6.26
- ZVRA N/A
- Revenue Next Year
- EBS $2.42
- ZVRA $384.62
- P/E Ratio
- EBS N/A
- ZVRA N/A
- Revenue Growth
- EBS 2.05
- ZVRA 47.85
- 52 Week Low
- EBS $1.42
- ZVRA $4.20
- 52 Week High
- EBS $15.10
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- EBS 60.60
- ZVRA 45.71
- Support Level
- EBS $9.20
- ZVRA $7.61
- Resistance Level
- EBS $10.63
- ZVRA $8.10
- Average True Range (ATR)
- EBS 0.67
- ZVRA 0.37
- MACD
- EBS 0.05
- ZVRA -0.02
- Stochastic Oscillator
- EBS 81.86
- ZVRA 40.30
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.